drugset / Trial / NCT02287129
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Metabolic and Molecular Response evaluation for the individualization of therapy in adenocarcinomas of the gastroesophageal junction by evaluation of the R0 resection rate for patients with metabolically (ie, according to PET criteria) chemotherapy-resistant locally advanced AEG, who receive an intensified neoadjuvant chemoradiotherapy (INRCT). Additonal efforts will be done by investigation of molecular and metabolic biomarkers in relation to their predictive and prognostic value by correlating them with histopathologic responses and clinical outcome in an exploratory approach.
Timeline
- Start
- 2014-12-05
- Primary completion
- 2020-08-07
- Completion
- 2020-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 mg/ml | — |
| Subject | Paclitaxel | Small molecule | 50 mg/m2 | — |
| Background | Capecitabine | Small molecule | 625 mg/m2 | — |
| Background | Epirubicin | Small molecule | 50 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | fluorouracil | Small molecule | 200 mg/m2 | — |